Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer (Q44365458)

2 December 2017

title

Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer (English)

1 reference

2 December 2017

1 reference

F Petrelli

1

1 reference

2 December 2017

S Barni

series ordinal

2

1 reference

2 December 2017

publication date

16 August 2012

1 reference

2 December 2017

1 reference

2 December 2017

volume

24

1 reference

2 December 2017

issue

1

1 reference

2 December 2017

page(s)

186-192

1 reference

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Cancer treatment and survivorship statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Progression-free survival is a surrogate for survival in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Detecting an overall survival benefit that is derived from progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Onco

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Progression-free survival: meaningful or simply measurable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Worldwide variations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDS289

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS289

1 reference

2 December 2017

1 reference